Quest Diagnostics has introduced two Post-COVID-19 panels for consumers that offer information about lingering health issues associated with previous COVID-19 virus infections.

Supplies of laboratory reagents, testing components and transport media are expected to normalize in the first half of 2023, ending shortages that date back to early in the pandemic, according to the Food and Drug Administration.

DiaSorin said late Friday that it has nabbed US Food and Drug Administration 510(k) clearance for a molecular assay that differentiates between infections with the SARS-CoV-2 and influenza A and B viruses.

Cue Health Inc., a healthcare technology company, reported financial results for the fourth quarter and full-year 2022.

BioMérieux reported Wednesday that its fourth quarter revenues rose 11 percent year over year.

QuidelOrtho Corporation, a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it has been granted a De Novo request from the U.S. Food and Drug Administration (FDA).

BGI Genomics said on Friday that its multiplexed test for SARS-CoV-2, influenza A, and influenza B is now included in the Australian Register of Therapeutic Goods.

By the end of 2022, there were 1,033,000 medical and health institutions in China, including 37,000 hospitals. The medical and health institutions in China possessed 9.75 million beds, of which hospitals possessed 7.66 million and township health centers had 1.45 million.